DMR-001 — NDA/BLA submission
H2 2026
We plan to complete additional regulatory submissions for DMR-001 in the second half of 2026 to expand the Phase 1/1b trial globally and enable two proof-of-concept readouts beginning mid-2027.Source filing
DMRA biotech catalysts & pipeline
DAMORA THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
DMR-002 — IND submission
H2 2026
We intend to submit an Investigational New Drug Application ("IND") or Clinical Trial Application ("CTA") for DMR-001 and DMR-002 in mid-2026 and the second half of 2026, respectively, and for DMR-003 in 2027.Source filing
DMR-002 — NDA/BLA submission
H2 2026
As we advance DMR-001, we plan to make our first regulatory submissions for DMR-002 in the second half of 2026 and for DMR-003 in 2027.Source filing
DMR-003 — IND submission
2027
We intend to submit an Investigational New Drug Application ("IND") or Clinical Trial Application ("CTA") for DMR-001 and DMR-002 in mid-2026 and the second half of 2026, respectively, and for DMR-003 in 2027.Source filing
DMR-003 — NDA/BLA submission
in 2027
As we advance DMR-001, we plan to make our first regulatory submissions for DMR-002 in the second half of 2026 and for DMR-003 in 2027.Source filing
GB3226 (BRM-1420) — Initial data
2027
We would expect initial clinical data for the Phase 1 trial to be available in 2027.Source filing
DMR-001 — Topline data
Mid 2027
We intend to file an IND or CTA for DMR-001 in mid-2026 and initiate a Phase 1 trial in ET and MF patients with a subcutaneous formulation thereafter, subject to regulatory approval, with two proof-of-concept readouts expected beginning mid-2027.Source filing